The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Identifieur interne : 000563 ( Main/Exploration ); précédent : 000562; suivant : 000564The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Auteurs : Samuel Aballéa [Royaume-Uni] ; Jose Ram N De Juanes ; Marco Barbieri ; Monique Martin ; Jeremy Chancellor ; Itziar Oyagüez ; Bertrand Verwee ; Nathalie LargeronSource :
- Vaccine [ 0264-410X ] ; 2007.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Analyse coût-bénéfice (MeSH), Années de vie ajustées sur la qualité (MeSH), Espagne (épidémiologie), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains (MeSH), Modèles économiques (MeSH), Vaccination (économie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- économie : Grippe humaine, Vaccination, Vaccins antigrippaux.
- épidémiologie : Espagne, Grippe humaine.
- Adulte d'âge moyen, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Humains, Modèles économiques.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Cost-Benefit Analysis (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Middle Aged (MeSH), Models, Economic (MeSH), Quality-Adjusted Life Years (MeSH), Spain (epidemiology), Vaccination (economics).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Spain.
- economics : Influenza, Human, Vaccination.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Cost-Benefit Analysis, Humans, Middle Aged, Models, Economic, Quality-Adjusted Life Years.
Abstract
An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental cost-effectiveness ratios were estimated at euro14,919 per quality-adjusted life-year (QALY) gained and euro9731 per life-year gained. From societal perspective, the corresponding results were euro4149 per QALY and euro2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective.
DOI: 10.1016/j.vaccine.2007.07.033
PubMed: 17764790
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.</title><author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name><affiliation wicri:level="1"><nlm:affiliation>i3 Innovus, Uxbridge, UK. saballea@i3innovus.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>i3 Innovus, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="De Juanes, Jose Ram N" sort="De Juanes, Jose Ram N" uniqKey="De Juanes J" first="Jose Ram N" last="De Juanes">Jose Ram N De Juanes</name></author><author><name sortKey="Barbieri, Marco" sort="Barbieri, Marco" uniqKey="Barbieri M" first="Marco" last="Barbieri">Marco Barbieri</name></author><author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name></author><author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name></author><author><name sortKey="Oyaguez, Itziar" sort="Oyaguez, Itziar" uniqKey="Oyaguez I" first="Itziar" last="Oyagüez">Itziar Oyagüez</name></author><author><name sortKey="Verwee, Bertrand" sort="Verwee, Bertrand" uniqKey="Verwee B" first="Bertrand" last="Verwee">Bertrand Verwee</name></author><author><name sortKey="Largeron, Nathalie" sort="Largeron, Nathalie" uniqKey="Largeron N" first="Nathalie" last="Largeron">Nathalie Largeron</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17764790</idno><idno type="pmid">17764790</idno><idno type="doi">10.1016/j.vaccine.2007.07.033</idno><idno type="wicri:Area/Main/Corpus">00557</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00557</idno><idno type="wicri:Area/Main/Curation">000557</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000557</idno><idno type="wicri:Area/Main/Exploration">000557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.</title><author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name><affiliation wicri:level="1"><nlm:affiliation>i3 Innovus, Uxbridge, UK. saballea@i3innovus.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>i3 Innovus, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="De Juanes, Jose Ram N" sort="De Juanes, Jose Ram N" uniqKey="De Juanes J" first="Jose Ram N" last="De Juanes">Jose Ram N De Juanes</name></author><author><name sortKey="Barbieri, Marco" sort="Barbieri, Marco" uniqKey="Barbieri M" first="Marco" last="Barbieri">Marco Barbieri</name></author><author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name></author><author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name></author><author><name sortKey="Oyaguez, Itziar" sort="Oyaguez, Itziar" uniqKey="Oyaguez I" first="Itziar" last="Oyagüez">Itziar Oyagüez</name></author><author><name sortKey="Verwee, Bertrand" sort="Verwee, Bertrand" uniqKey="Verwee B" first="Bertrand" last="Verwee">Bertrand Verwee</name></author><author><name sortKey="Largeron, Nathalie" sort="Largeron, Nathalie" uniqKey="Largeron N" first="Nathalie" last="Largeron">Nathalie Largeron</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cost-Benefit Analysis (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Middle Aged (MeSH)</term><term>Models, Economic (MeSH)</term><term>Quality-Adjusted Life Years (MeSH)</term><term>Spain (epidemiology)</term><term>Vaccination (economics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Années de vie ajustées sur la qualité (MeSH)</term><term>Espagne (épidémiologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Modèles économiques (MeSH)</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Humans</term><term>Middle Aged</term><term>Models, Economic</term><term>Quality-Adjusted Life Years</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Humains</term><term>Modèles économiques</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental cost-effectiveness ratios were estimated at euro14,919 per quality-adjusted life-year (QALY) gained and euro9731 per life-year gained. From societal perspective, the corresponding results were euro4149 per QALY and euro2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17764790</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2007</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>39-40</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.</ArticleTitle><Pagination><MedlinePgn>6900-10</MedlinePgn></Pagination><Abstract><AbstractText>An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental cost-effectiveness ratios were estimated at euro14,919 per quality-adjusted life-year (QALY) gained and euro9731 per life-year gained. From societal perspective, the corresponding results were euro4149 per QALY and euro2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aballéa</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>i3 Innovus, Uxbridge, UK. saballea@i3innovus.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Juanes</LastName><ForeName>Jose Ramón</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Barbieri</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chancellor</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Oyagüez</LastName><ForeName>Itziar</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Verwee</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Largeron</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17764790</ArticleId><ArticleId IdType="pii">S0264-410X(07)00783-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2007.07.033</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Barbieri, Marco" sort="Barbieri, Marco" uniqKey="Barbieri M" first="Marco" last="Barbieri">Marco Barbieri</name><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name><name sortKey="De Juanes, Jose Ram N" sort="De Juanes, Jose Ram N" uniqKey="De Juanes J" first="Jose Ram N" last="De Juanes">Jose Ram N De Juanes</name><name sortKey="Largeron, Nathalie" sort="Largeron, Nathalie" uniqKey="Largeron N" first="Nathalie" last="Largeron">Nathalie Largeron</name><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name><name sortKey="Oyaguez, Itziar" sort="Oyaguez, Itziar" uniqKey="Oyaguez I" first="Itziar" last="Oyagüez">Itziar Oyagüez</name><name sortKey="Verwee, Bertrand" sort="Verwee, Bertrand" uniqKey="Verwee B" first="Bertrand" last="Verwee">Bertrand Verwee</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000563 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000563 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17764790
|texte= The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17764790" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |